4D Molecular Therapeutics (NASDAQ:FDMT) Issues Earnings Results

Key Points

• 4D Molecular Therapeutics reported a quarterly loss of $1.08 per share, missing the $1.05 consensus estimate by $0.03. Revenue was $4.14 million, slightly above the $4.13 million estimate.
• The stock fell $0.87 to $12.12 in Thursday trading. Analysts maintain a “Moderate Buy” consensus rating, with an average price target of $30.22.
• Insiders sold 122,155 shares worth about $1.64 million over the past 90 days; company insiders own 7.9% of the stock.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) released its earnings results on Thursday. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by ($0.03), FiscalAI reports. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. The firm had revenue of $4.14 million for the quarter, compared to the consensus estimate of $4.13 million.

4D Molecular Therapeutics Price Performance

NASDAQ FDMT traded down $0.87 during trading hours on Thursday, reaching $12.12. The company's stock had a trading volume of 895,895 shares, compared to its average volume of 868,418. The firm's 50-day moving average price is $13.25 and its 200-day moving average price is $11.03. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics has a 1 year low of $6.96 and a 1 year high of $16.93. The company has a market capitalization of $669.56 million, a price-to-earnings ratio of -4.61 and a beta of 2.92.

Analyst Ratings Changes

A number of research firms have weighed in on FDMT. Citigroup reiterated a "buy" rating on shares of 4D Molecular Therapeutics in a research report on Thursday, October 22nd. Chardan Capital lowered their target price on shares of 4D Molecular Therapeutics from $26.00 to $25.00 and set a "buy" rating on the stock in a research note on Tuesday, October 6th. Cantor Fitzgerald upgraded shares of 4D Molecular Therapeutics from a "neutral" rating to an "overweight" rating and set a $20.00 target price on the stock in a research note on Monday, September 14th. B. Riley Financial reaffirmed a "buy" rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Finally, The Goldman Sachs Group reiterated a "buy" rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, 4D Molecular Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $30.22.

Insiders Place Their Bets

In other 4D Molecular Therapeutics news, insider David Kirn sold 58,333 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $12.92, for a total transaction of $753,662.36. Following the completion of the sale, the insider directly owned 709,153 shares of the company's stock, valued at $9,162,256.76. This trade represents a 7.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 122,155 shares of company stock valued at $1,635,925. Corporate insiders own 7.90% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. is a biotechnology company developing genetic medicines for serious diseases. Its research focuses on adeno-associated virus (AAV) gene therapies, which use engineered viral vectors to deliver therapeutic genetic material to cells. The company's proprietary Therapeutic Vector Evolution platform is designed to create AAV vectors with targeted properties, including the ability to reach specific tissues. Its investigational programs have included treatments for retinal diseases, cystic fibrosis and Fabry disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.